Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel
NASDAQ:KRSA

Cyclerion Therapeutics Q3 2026 Earnings Date & Estimates

Cyclerion Therapeutics logo
$30.80 -1.16 (-3.61%)
As of 12:37 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cyclerion Therapeutics is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cyclerion Therapeutics in Q3 2026

Cyclerion Therapeutics is expected to post earnings of -$50.40 per share on revenue of $550 thousand. In the same quarter a year earlier Cyclerion Therapeutics reported -$2.10 per share on revenue of $875 thousand. Cyclerion Therapeutics last reported on May 12, 2026, posting -$5.32 per share and beating the -$120.40 consensus estimate.

Consensus Estimates

Consensus EPS
-$50.40
Expected Revenue
$550 thousand
Prior-Year EPS
-$2.10
Prior-Year Revenue
$875 thousand
Expected Revenue Growth
-37.1%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
-$5.32 (Beat by +$115.08)

Prepare for the Q3 2026 Call

Cyclerion Therapeutics Q3 2026 Earnings FAQ

Cyclerion Therapeutics (NASDAQ:KRSA) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Cyclerion Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cyclerion Therapeutics to post earnings of -$50.40 per share for Q3 2026.

The consensus revenue estimate for Cyclerion Therapeutics is $550 thousand for Q3 2026.

Cyclerion Therapeutics Earnings Headlines

Korsana Biosciences to Participate in Upcoming Investor Conferences
November 2 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/02/3393735/0/en/korsana-biosciences-to-participate-in-upcoming-investor-conferences.html
Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Stock Has Average Target Price of $53.00 According to Analysts
October 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31162914
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
November 4 at 1:00 AM  |  Crypto 101 Media (Ad)
Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3358102/0/en/korsana-biosciences-completes-closing-of-merger-with-cyclerion-therapeutics-and-previously-announced-private-placement-of-380-million.html
Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline
April 21, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/cyclerion-therapeutics-cycn-merges-korsana-141501551.html
Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here?
April 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/penny-stock-cycn-surged-more-131538935.html
See More Cyclerion Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclerion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclerion Therapeutics and other key companies, straight to your email.

About Cyclerion Therapeutics

Cyclerion Therapeutics (NASDAQ:KRSA) was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis. These products were investigational and had not been approved for commercial use.

The company operated primarily through research and development activities and clinical collaborations rather than through a commercial product business. Cyclerion was previously led by Peter Hecht, who served as chief executive officer. Public information about the company’s current operations and the relationship between Cyclerion Therapeutics and the cited NASDAQ symbol KRSA is limited; the company was historically associated with the ticker CYCN.

View Cyclerion Therapeutics Profile
Earnings Tools